Carruthers Alastair, Sadick Neil, Brandt Frederic, Trindade de Almeida Ada Regina, Fagien Steve, Goodman Greg J, Raspaldo Herve, Smith Kevin, Darmody Sarah, Gallagher Conor J, Street James, Romagnano Linda
*Carruthers Clinical Research, Vancouver, Canada; †Sadick Research Group, New York, New York; ‡Dr. Brandt Dermatology Associates, Coral Gables, Florida; §Hospital Do Servidor Publico Municipal, Sao Paulo, Brazil; ‖Aesthetic Eyelid Plastic Surgery, Boca Raton, Florida; ¶Monash University, Clayton, Victoria, Australia; #Cannes Private Clinic, Cannes, France; **Niagara Falls Dermatology and Skin Care Center, Niagara Falls, Canada; ††Allergan, Inc., Irvine, California; ‡‡Peloton Advantage, Parsippany, New Jersey.
Dermatol Surg. 2015 Jun;41(6):693-701. doi: 10.1097/DSS.0000000000000340.
Little information exists on how facial aesthetic treatments are incorporated into aesthetic regimens.
Assess the evolution of facial aesthetic treatments in patients receiving long-term continuous onabotulinumtoxinA treatment.
This international retrospective chart review included patients with ≥5 years of continuous onabotulinumtoxinA treatments including ≥1 glabellar lines treatment/year. Charts were reviewed for facial areas treated, number of treatments, doses/treatment visit, concomitant aesthetic procedures, and onabotulinumtoxinA-related adverse events.
Data were collected from 5,112 onabotulinumtoxinA treatment sessions for 194 patients over an average of 9.1 years. Dosing was relatively stable over time; however, interinjection intervals increased. Glabellar lines' treatment temporally preceded crow's feet lines and forehead lines' treatment. A majority of patients (85%) also received treatment with fillers. Cumulative increases in onabotulinumtoxinA treatments occurred over time and by facial area corresponding with increases in treatments with injectable fillers, energy-based devices, and prescription topical creams. The longer the patients were treated, the younger they perceived themselves to look. Rates of adverse events were low.
OnabotulinumtoxinA treatment evolved over time, coinciding with growth of the facial aesthetics market. Additional treatment modalities were added as complements to onabotulinumtoxinA. Long-term continuous onabotulinumtoxinA injections are an important component of contemporary facial aesthetic treatment regimens.
关于面部美容治疗如何纳入美容方案的信息很少。
评估接受长期持续注射A型肉毒毒素治疗的患者面部美容治疗的演变情况。
这项国际回顾性图表审查纳入了连续接受A型肉毒毒素治疗≥5年且每年至少进行1次眉间纹治疗的患者。审查图表以了解治疗的面部区域、治疗次数、每次治疗的剂量、同时进行的美容手术以及与A型肉毒毒素相关的不良事件。
在平均9.1年的时间里，收集了194例患者5112次A型肉毒毒素治疗的数据。随着时间的推移，剂量相对稳定；然而，注射间隔时间增加。眉间纹治疗在时间上先于鱼尾纹和额头纹治疗。大多数患者（85%）还接受了填充剂治疗。随着时间的推移，A型肉毒毒素治疗的累积增加与面部区域相对应，这与注射填充剂、能量设备和处方外用乳膏治疗的增加相一致。患者接受治疗的时间越长，他们感觉自己看起来越年轻。不良事件发生率较低。
随着时间的推移，A型肉毒毒素治疗不断演变，这与面部美容市场的增长相吻合。增加了其他治疗方式作为A型肉毒毒素的补充。长期持续注射A型肉毒毒素是当代面部美容治疗方案的重要组成部分。
